Novo shares jump 6% as Wegovy pill sales beat
CNBC · RSS · · AI-summarised by FinFlash
Novo Nordisk shares rose 6% after the drugmaker reported quarterly earnings ahead of expectations, with sales of its Wegovy pill blowing past estimates. The company also raised its outlook. The beat and guidance hike suggest demand for oral obesity treatments is holding up, a positive signal for investors in the weight-loss drug sector.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.